Subscriber Authentication Point
lvrea
Home All issues Volume 24 / No 4 (Juillet 2015) Réanimation, 24 4 (2015) 367-378 References
Free Access
Issue
Réanimation
Volume 24, Number 4, Juillet 2015
Quid des patients spécifiques ?
Page(s) 367 - 378
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1086-y
Published online 13 June 2015
  • ObÉpi-Roche (2012) http://www.roche.fr/content/dam/corporate/roche_fr/doc/obepi_2012.pdf [Google Scholar]
  • Finucane MM, Stevens GA, Cowan MJ, et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:557–67 [CrossRef] [PubMed] [Google Scholar]
  • Ng M, Fleming T, Robinson M, et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:766–81 [CrossRef] [PubMed] [Google Scholar]
  • Lee SY, Gallagher D (2008) Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 11:566–72 [CrossRef] [PubMed] [Google Scholar]
  • Poirier P, Giles TD, Bray GA, et al (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113:898–18 [CrossRef] [PubMed] [Google Scholar]
  • Guerra F, Mancinelli L, Angelini L, et al (2011) The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One 6:e16630 [CrossRef] [PubMed] [Google Scholar]
  • Abd El-Kader SM, El-Den Ashmawy EM (2015) Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 7:846–58 [CrossRef] [PubMed] [Google Scholar]
  • Felizardo RJ, da Silva MB, Aguiar CF, et al (2014) Obesity in kidney disease: a heavyweight opponent. World J Nephrol 3:50–63 [CrossRef] [PubMed] [Google Scholar]
  • Young JF, Luecke RH, Pearce BA, et al (2009) Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A 72:527–40 [CrossRef] [PubMed] [Google Scholar]
  • Bouloumie A, Curat CA, Sengenes C, et al (2005) Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8:347–54 [CrossRef] [PubMed] [Google Scholar]
  • Padwal R, Brocks D, Sharma AM (2010) A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 11:41–50 [CrossRef] [PubMed] [Google Scholar]
  • Schwartz SN, Pazin GJ, Lyon JA, et al (1978) A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 138:499–505 [CrossRef] [PubMed] [Google Scholar]
  • Abernethy DR, Divoll M, Greenblatt DJ, et al (1982) Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 31:783–90 [CrossRef] [PubMed] [Google Scholar]
  • Abernethy DR, Greenblatt DJ (1985) Ibuprofen disposition in obese individuals. Arthritis Rheum 28:1117–21 [CrossRef] [PubMed] [Google Scholar]
  • Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans. An update. Clin Pharmacokinet 11:199–213 [CrossRef] [PubMed] [Google Scholar]
  • Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87 [CrossRef] [PubMed] [Google Scholar]
  • Greenblatt DJ, Arendt RM, Abernethy DR, et al (1983) In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth 55:985–9 [CrossRef] [PubMed] [Google Scholar]
  • Servin F, Farinotti R, Haberer JP, et al (1993) Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 78:657–65 [CrossRef] [PubMed] [Google Scholar]
  • Brand L, Mark LC, Snell MM, et al (1963) Physiologic disposition of methohexital in man. Anesthesiology 24:331–5 [CrossRef] [PubMed] [Google Scholar]
  • Zini R, Riant P, Barre J, et al (1990) Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). Clin Pharmacokinet 19:218–29 [CrossRef] [PubMed] [Google Scholar]
  • Brill MJ, Diepstraten J, van Rongen A, et al (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51:277–304 [CrossRef] [PubMed] [Google Scholar]
  • Ulvestad M, Skottheim IB, Jakobsen GS, et al (2013) Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther 93:275–82 [CrossRef] [PubMed] [Google Scholar]
  • Brill MJ, van Rongen A, Houwink AP, et al (2014) Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet 53:931–41 [CrossRef] [PubMed] [Google Scholar]
  • Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102:740–4 [CrossRef] [PubMed] [Google Scholar]
  • Ewy GA, Groves BM, Ball MF, et al (1971) Digoxin metabolism in obesity. Circulation 44:810–4 [CrossRef] [PubMed] [Google Scholar]
  • Schwartz AE, Matteo RS, Ornstein E, et al (1991) Pharmacokinetics of sufentanil in obese patients. Anesth Analg 73:790–3 [PubMed] [Google Scholar]
  • Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621–5 [CrossRef] [PubMed] [Google Scholar]
  • Dvorchik B, Arbeit RD, Chung J, et al (2004) Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48:2799–807 [CrossRef] [PubMed] [Google Scholar]
  • Pai MP, Cojutti P, Pea F (2014) Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. Clin Pharmacokinet 53:753–62 [CrossRef] [PubMed] [Google Scholar]
  • Pai MP, Bearden DT (2007) Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27:1081–91 [CrossRef] [PubMed] [Google Scholar]
  • Levey AS, Bosch JP, Lewis JB, et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–70 [CrossRef] [PubMed] [Google Scholar]
  • Miller AA, Spencer SJ (2014) Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun 42:10–21 [CrossRef] [PubMed] [Google Scholar]
  • Blum K, Han D, Femino J, et al (2014) Systematic evaluation of “compliance” to prescribed treatment medications and “abstinence” from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One 9:e104275 [CrossRef] [PubMed] [Google Scholar]
  • Balachandran JS, Masa JF, Mokhlesi B (2014) Obesity hypoventilation syndrome epidemiology and diagnosis. Sleep Med Clin 9:341–7 [CrossRef] [PubMed] [Google Scholar]
  • Juvin P, Lavaut E, Dupont H, et al (2003) Difficult tracheal intubation is more common in obese than in lean patients. Anesth Analg 97:595–600 [CrossRef] [PubMed] [Google Scholar]
  • Ahmad S, Nagle A, McCarthy RJ, et al (2008) Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg 107:138–43 [CrossRef] [PubMed] [Google Scholar]
  • Toma O, Suntrup P, Stefanescu A, et al (2011) Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg 113:730–7 [CrossRef] [PubMed] [Google Scholar]
  • Shah DK, Missmer SA, Correia KF, et al (2014) Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 99:1314–21 [CrossRef] [PubMed] [Google Scholar]
  • Sanderink GJ, Le Liboux A, Jariwala N, et al (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72:308–18 [CrossRef] [PubMed] [Google Scholar]
  • Lloret Linares C, Hajj A, Poitou C, et al (2011) Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. Obes Surg 21:1257–64 [CrossRef] [PubMed] [Google Scholar]
  • May CN, Calzavacca P, Ishikawa K, et al (2012) Novel targets for sepsis-induced kidney injury: the glomerular arterioles and the sympathetic nervous system. Exp Physiol 97:1168–77 [CrossRef] [PubMed] [Google Scholar]
  • Cheatham SC, Fleming MR, Healy DP, et al (2014) Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 54:324–30 [CrossRef] [PubMed] [Google Scholar]
  • Kays MB, Fleming MR, Cheatham SC, et al (2014) Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother 48:178–86 [CrossRef] [PubMed] [Google Scholar]
  • Dvorchik BH, Damphousse D (2005) The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 45:48–56 [CrossRef] [PubMed] [Google Scholar]
  • Bhalodi AA, Papasavas PK, Tishler DS, et al (2013) Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 57:1144–9 [CrossRef] [PubMed] [Google Scholar]
  • Schumann R, Jones SB, Cooper B, et al (2009) Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004–2007. Obesity (Silver Spring) 17:889–94 [CrossRef] [PubMed] [Google Scholar]
  • Ingrande J, Lemmens HJ (2010) Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 105:i16–i23 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.